GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Detection and Characterisation of Varicella Zoster Virus From Dermal Lesions of Chickenpox-infected Patients
- First Posted Date
- 2005-08-08
- Last Posted Date
- 2019-02-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 36
- Registration Number
- NCT00127608
- Locations
- 🇨🇿
GSK Investigational Site, Praha 8, Czechia
Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
- First Posted Date
- 2005-08-05
- Last Posted Date
- 2016-09-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1439
- Registration Number
- NCT00126997
- Locations
- 🇵🇱
GSK Investigational Site, Trzebnica, Poland
Evaluate 4 Different Formulations of Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 15-19 Yrs
- Conditions
- First Posted Date
- 2005-08-05
- Last Posted Date
- 2016-09-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 125
- Registration Number
- NCT00126945
- Locations
- 🇩🇰
GSK Investigational Site, Aarhus N, Denmark
Study in Children to Evaluate the Immunogenicity and Safety of 4 Formulations of GSK Bio MenACWY-TT Conjugate Vaccine
- First Posted Date
- 2005-08-05
- Last Posted Date
- 2016-10-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 508
- Registration Number
- NCT00126984
- Locations
- 🇩🇪
GSK Investigational Site, Berlin, Germany
Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
- First Posted Date
- 2005-08-05
- Last Posted Date
- 2016-09-26
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT00127010
- Locations
- 🇳🇱
GSK Investigational Site, Rotterdam, Netherlands
Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
- First Posted Date
- 2005-08-05
- Last Posted Date
- 2016-09-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 944
- Registration Number
- NCT00127023
- Locations
- 🇩🇪
GSK Investigational Site, Hamburg, Germany
Screening Protocol To Determine Eligibility For Studies Of The Chemokine Coreceptor 5 (CCR5) Antagonist GW873140
- Conditions
- First Posted Date
- 2005-07-26
- Last Posted Date
- 2011-03-29
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT00123890
- Locations
- 🇩🇪
GSK Investigational Site, Hamburg, Germany
COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria
- Conditions
- First Posted Date
- 2005-07-26
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1220
- Registration Number
- NCT00123903
- Locations
- 🇵🇷
GSK Investigational Site, San Juan, Puerto Rico
Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18
- Conditions
- Interventions
- First Posted Date
- 2005-07-22
- Last Posted Date
- 2018-08-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 18729
- Registration Number
- NCT00122681
- Locations
- 🇬🇧
GSK Investigational Site, Waterloo, Liverpool, United Kingdom
Evaluation of GW406381 in Treating Adults With Osteoarthritis Of The Knee
- Conditions
- First Posted Date
- 2005-07-19
- Last Posted Date
- 2017-01-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1340
- Registration Number
- NCT00120900
- Locations
- 🇸🇪
GSK Investigational Site, Helsingborg, Sweden